A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients

Inclusion criteria

• Male or females outpatients aged ≥ 16 years old with stable mild to moderate persistent asthma; Stability was assessed the patient remained in the same severity class (mild, moderate) and had no acute exacerbations by investigator judgment during the past 14 days;
• Pulmonary function test:

• Improvement ≥12% reversibility in FEV1 or FVC following administration of an inhaled β2-agonist before the study or ;
• Positive result of Broncho-provocation test (PC20 ≤ 32 mg/ml) before the study.
• Baseline forced expiratory volume in one second 60% ≤(FEV1)≤ 90% of predicted value on entry of the study;

Exclusion criteria

• Hypersensitivity to β2-agonist or lactose;
• Hospitalization due to asthma during the previous 3months;
• Respiratory tract infection requiring treatment with antibiotics in the previous 4 weeks;
• Oral or systemic corticosteroids in the previous 4weeks;
• Inadequately controlled hyperthyroidism;
• Severe hepatic or renal or cardiovascular disease as judged by the investigator;
• Patients receive an investigational drug within 30 days prior to admission to the study;
• Patients with significant alcohol, drug or medication abuse as judged by the investigator;
• Females who are pregnant or breast-feeding; (exception: Females of child-bearing age might be included, if in the opinion of the investigator, they are using adequate contraceptive precautions).